Immatics’ PRAME-Directed TCR T-Cell Therapy Drives Deep Remission in Pediatric Solid Tumor Case

Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TC...

April 21, 2026 | Tuesday | News
Swissmedic Approves Bavarian Nordic’s VIMKUNYA®, Marking Fourth Global Authorization for Chikungunya Vaccine

Bavarian Nordic A/S announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA® (recombinant, adsorbed) for active i...

April 17, 2026 | Friday | News
Sana Biotechnology and Mayo Clinic Partner to Advance SC451 Cell Therapy for Type 1 Diabetes

Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patie...

April 15, 2026 | Wednesday | News
OncoC4 Initiates Phase 1/2 Trial of Anti-SIGLEC 10 Antibody in Alzheimer’s Disease

OncoC4 Inc., a late clinical stage biopharmaceutical company, announced first participant's dosing following the clearance of the Investigational New Dru...

April 13, 2026 | Monday | News
Thermo Fisher Scientific Partners with PRECISE to Power Singapore’s Landmark SG100K Biobank Study with Integrated Proteomics

  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, \announced a strategic collaboration with Precision Health Research...

April 10, 2026 | Friday | News
Innovaccer, Infinia Forge Alliance to Accelerate UAE’s Digital Health Transformation

Innovaccer Inc., a leading healthcare AI company, and Infinia Technologies, a next-generation digital transformation company and a subsidiary of Sirius I...

April 10, 2026 | Friday | News
Curanex Pharmaceuticals, Inc. Expands Pipeline to Target Cancer Cachexia, Addressing Major Oncology Supportive-Care Gap

Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (&...

April 07, 2026 | Tuesday | News
BioCardia, Inc. Submits CardiAMP HF Data to FDA, Eyes Accelerated Approval Pathway for Heart Failure Therapy

BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dis...

April 07, 2026 | Tuesday | News
CellCarta And Pillar Biosciences Partner To Accelerate Biomarker Driven Oncology Trials

The partnership pairs Pillar's portfolio of oncoReveal® kitted NGS panels with CellCarta's global laboratory network and biomarker expertise to reduc...

April 03, 2026 | Friday | News
Oncotelic Therapeutics Partners with TechForce Robotics to Commercialize AI-Driven GMP Robotics Platform

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-dr...

April 03, 2026 | Friday | News
Lilly To Acquire Centessa Strengthening OX2R Pipeline For Sleep Wake Disorders

Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pip...

April 02, 2026 | Thursday | News
Biomea Advances Icovamenib into Phase II With Dual COVALENT Studies in Type 2 Diabetes

COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled wit...

April 01, 2026 | Wednesday | News
Mayo Clinic Secures $75 Million Grainger Family Gift to Power Next-Generation Healthcare Campus

Mayo Clinic announces a gift of $75 million from the Thomas and Elizabeth Grainger family to support Bold. Forward. Unbound. in Rochester, Mayo Clinic's ...

March 30, 2026 | Monday | News
Novo Nordisk and The United Laboratories International Holdings Limited Report Strong Phase 2 Results for Triple Agonist UBT251 in Type 2 Diabetes

  UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nord...

March 26, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close